Antares Pharma Inc

Antares Pharma — Jefferies 2017 Healthcare Conference

16 slides from Antares Pharma's conference presentation, Jun 8, 2017

  1. Slide 1: Jefferies 2017 Healthcare Conference

    NASDAQ: ATRS Jefferies 2017 Healthcare Conference June 8, 2017 Robert F. Apple President and Chief Executive Officer Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those desc

  3. Slide 3: Antares Pharma: A Growing, Revenue Generating Specialty Pharmaceutical Company

    Antares Pharma A Growing, Revenue Generating State-of-the-Art Specialty Pharmaceutical Company An Innovative Leader in Self-Administered Injection Technology Two combination products approved and on the U.S. market (OTREXUP®, Sumatriptan) and one combination product approved in Europe awaiting marke

  4. Slide 4: QuickShot Testosterone = XYOSTED

    QuickShot® Testosterone = XYOSTED™

  5. Slide 5: XYOSTED NDA filing accepted, PDUFA date 10/20/17

    XYOSTED™ NDA filing accepted February – PDUFA date 10/20/17 Possible launch in late 2017 / early 2018 Launch plan: ~60 Sales Representatives focusing on high decile prescribers Hiring of reps to commence Q417 (assuming FDA approval) – DM interviews underway Third party payer discussions have begun t

  6. Slide 6: New Drug Application for XYOSTED

    New Drug Application for XYOSTED™ Satisfaction with self-injections, ease-of-use, self-image, and injection site reactions increased from Baseline to Week 12 1,510 of 1,519 (99.4%) of observed injections in the 52 week P3 “003” study were reported as painless Overall improvement was observed across

  7. Slide 7: VIBEX Sumatriptan Auto Injector

    VIBEX® Sumatriptan Auto Injector Q117 product revenue of $3.6 million generated from the shipment of sumatriptan to Teva – $12.7 million since launch including pre-launch shipments Market Share week ended 5/19/17 - 28%* VIBEX® Sumatriptan Injection USP *Symphony Health Solutions Weekly TRx Data 28%*

  8. Slide 8: OTREXUP Quarterly Revenue Progression

    OTREXUP® Quarterly Revenue Progression Revenue in Millions $3.8 $3.3 $3.3 $3.6 $3.3 $3 $2.8 $2.6 $1.7 $0.2 *Includes $1.3 million in previously deferred revenue from sales in prior periods.

  9. Slide 9: Generic Byetta (exenatide) Multi-Dose Pen

    Generic Byetta® (exenatide) Multi-Dose Pen Teva announced settlement with AstraZeneca and Amylin which allows Teva to launch on October 15, 2017, pending FDA approval Teva filed ANDA in December 2014 and it is under FDA review – Antares believes Teva has first to file status and 180 days of marketin

  10. Slide 10: VIBEX Epinephrine

    VIBEX® Epinephrine Teva filed ANDA amendment with FDA in December 2014, Complete Response Letter (CRL) issued February 2016, Teva submitted responses to CRL in Q117 and they are targeting a launch in early 2018 Shipped $500k in devices to Teva in Q117 and ~$19.5 million to date Agreement with Teva –

  11. Slide 11: Generic Forteo (teriparatide) Multi-Dose Pen

    Generic Forteo® (teriparatide) Multi-Dose Pen Teva ANDA accepted by FDA 2/16; Lilly filed a lawsuit in response to Teva’s Paragraph IV notice, 30 month stay expires in August 2018. Lilly has agreed not to sue Teva on the device patent (which expires in 2025) - last to expire orange book patent is no

  12. Slide 12: Makena

    Makena® AMAG/Makena® alliance began in 2014 Antares is using the QuickShot device to develop a once-weekly subcutaneous injection of Makena Potentially better patient compliance Potentially easier administration Currently administered IM with a large-gauge needle from a single dose vial, Auto-inject

  13. Slide 13: First Quarter 2017 Financial Results

    First Quarter 2017 Financial Results Three Months Ended Mar 31 Increase 2017 2016 (Decrease) OTREXUP $ 4,564 $ 3,310 38% Auto injector and pen injector devices 4,108 5,979 -31% Needle-free devices & components 1,364 1,552 -12% Total Product Sales 10,036 10,841 -7% Development revenue 1,622 1,098 48%

  14. Slide 14: Debt Financing From Hercules Capital

    Debt Financing From Hercules Capital Five year term loan agreement provides up to $35 million First tranche of $25 million was funded upon execution of the loan agreement Antares has an option to draw up to an additional $10 million upon achievement of a certain milestone Payments under the loan are

  15. Slide 15: ATRS Investment Considerations

    ATRS Investment Considerations A revenue generating Specialty Pharmaceutical Company poised for growth Ongoing Catalysts: XYOSTED™ NDA under active review at FDA – October 20, 2017 PDUFA date Sumatriptan Injection USP launched – TRx share after 9 months – ~28% and growing per latest TRx data Continu

  16. Slide 16: Jefferies 2017 Healthcare Conference

    NASDAQ: ATRS Jefferies 2017 Healthcare Conference June 8, 2017 Robert F. Apple President and Chief Executive Officer

Antares Pharma — Jefferies 2017 Healthcare Conference on 6ix